BMP7 and diabetes mellitus: BMP7 is currently FDA-approved (marketed as OP-1 by Stryker Biotech), under the Humanitarian Device Exemption, for utilization in long bone nonunions and recalcitrant nonunions (White et al., 2007), but has not yet been used in human clinical trials as a weight-loss or anti-diabetes drug.